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Introduction 
INTRODUCTION 
   
Glaucoma is the second leading cause of blindness worldwide 1 
accounting for about 67 million sufferers.   
 
In glaucoma there is characteristic optic neuropathy with irreversible 
damage to the retinal ganglion cells leading to optic nerve head damage 
associated with corresponding visual field loss for which elevated IOP is one of 
the important risk factors. 
 
Neovascular glaucoma (NVG) is a type of potentially devastating 
secondary glaucoma caused by fibrovascular membrane formation over the iris, 
angle of anterior chamber and trabecular meshwork leading to progressive angle 
closure.  
 
It is due to an ongoing pathology causing retinal ischemia, leading to 
production of vaso proliferative substances which diffuse into anterior segment, 
in turn causing new vessel growth over the iris and angle. The IOP is often 
difficult to control resulting in loss of vision.  
 
There are various modalities of treating this NVG. Retinal ischemia being 
the main cause should be treated for which the main stay of treatment is Pan 
Retinal Photocoagulation (PRP), which ablates the ischemic retina and reduces 
the VEGF production. IOP can be reduced medically by aqueous production 
reducing drugs; surgically by trabeculectomy and shunt surgeries.  
 
Raised IOP is more refractory to medical management alone. Due to new 
vessel growth, surgical mode of treatment has high incidence of complications 
and failure rate. Another effective and novel method is by counteracting the 
angiogenesis factor, VEGF, thereby reducing the new vessel formation over the 
iris and angle, by anti VEGF agents like Bevacizumab. The intravitreal use of the 
same has been studied with good results.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Aims of the study 
AIMS OF THE STUDY 
 
To evaluate the role of intravitreal Bevacizumab in Neovascular glaucoma:  
 
a. Evaluating regression of neovascularization of the iris  
b. IOP control 
c. Side effects  
d. Need of additional intervention following intravitreal Bevacizumab  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Review of literature 
 REVIEW OF LITERATURE 
 
NEOVASCULAR GLAUCOMA 
 
Neovascular glaucoma (NVG) is a type of potentially devastating 
secondary glaucoma caused by fibrovascular membrane formation over the iris, 
angle of anterior chamber and trabecular meshwork leading to progressive angle 
closure.  
 
The underlying pathology is retinal ischemia, leading to production of vaso 
proliferative substances which diffuse into anterior segment, in turn causing new 
vessel growth over the iris and angle. The IOP is often difficult to control resulting 
in loss of vision.   
    
HISTORY 
             
            As early as 1871, Pagenstecher documented eye with intraocular 
bleeding and elevated IOP as having hemorrhagic glaucoma2. 
 
The anatomical basis for NVG being the histological finding of new vessel 
on  the iris was first put forward by Coats in 1906 in an eye with CRVO3. 
     
In 1928, Salus described similar new vessels on iris of eyes of diabetic 
patients. With the introduction of clinical gonioscopy in 1963, Kurtz described his 
clinical observation of new vessels in the angle. 
 
In 1963, Weiss and colleagues proposed the term neovascular glaucoma 
as the glaucoma is caused by new vessels. Waston and Grant in 1968, proposed 
the term Neovascularization of Iris (NVI) rather than rubeosis iridis. Historically 
NVG was termed as hemorrhagic glaucoma, thrombotic glaucoma, congestive 
glaucoma, rubeotic glaucoma. 
 
CAUSES OF NEOVASCULAR GLAUCOMA 
The common causes of NVG are Diabetic retinopathy (43 %), and CRVO 
(37 %), Carotid artery occlusive disease (CAOD). Inflammatory without retinal 
ischemia accounts for only 3 %. 
 
OCULAR VASCULAR DISEASES 
A. Retinal vascular occlusive diseases 
1. Central retinal vein occlusion. 
2. Hemi retinal vein occlusion. 
3. Branch retinal vein occlusion 
 
B. Diabetic retinopathy. 
C. Eales disease 
D. Sickle cell retinopathy. 
E. Coats disease 
F. PHPV 
G. Ocular tumors 
1. Retinoblastoma 
2. Uveal melanoma 
3. Metastatic tumor 
 
OTHER OCULAR DISEASES 
A. Inflammatory diseases  
1. Chronic uveitis 
2. Vogt – koyanagi – harada syndrome 
3. Endophthalmitis 
4. Syphilitic retinitis 
5. Sympathetic ophthalmitis 
B. Long standing  rhegmatogenous rd 
C. Sticklers syndrome  
 
 EXTRA OCULAR VASCULAR DISEASES 
 
1. Carotid occlusive disease 
2. Pulseless disease 
3. Giant cell arteritis 
4. Neurofibromatosis 
5. Caroticocavernous fistula   
 
    RADIATION 
a. External beam 
b. Charged particle – proton, helium 
c. Photoradiation. 
   
Central retinal vein occlusion 
CRVO is one of the most common causes of NVG. It accounts for one 
third of the cases. May be ischemic or nonischemic Nonischemic do not progress 
to NVG. 40 % of ischemic CRVO go for NVG. One third to half of the 
nonischemic type turns into Ischemic CRVO. Greater the degree of capillary 
nonperfusion, greater the chances of neovascularization. This is confirmed by 
fluorescein angiography. So careful follow up and repeated angiography is 
needed for a prophylactic treatment. 
 
Diabetes mellitus 
           Diabetic retinopathy (DR) is the second most common cause of NVG. In 
DM with PDR, the incidence of NVI is up to 65 %. The basic pathology being 
hyperglycemia, leading to retinal hypoxia. Onset of DR is related to the duration 
of the disease and is more with Type – II DM. Capillary dropout and retinal 
hypoxia occurs after surgical procedures like cataract extraction and vitrectomy 
in patients with DM. This adds to the risk of developing neovascularization. 
Increased incidence of NVI is also seen in absence or removal of diffusion barrier 
posterior capsule – anterior hyaloid. 
 
Carotid artery occlusive disease 
       CAOD is the third most common cause of NVG, accounting for 13 %. 
Decreased perfusion of cilliary body from CAOD may decrease aqueous 
production with normal or low IOP. 
 
Central artery occlusion 
        The incidence of isolated CRAO is 7 %. In CRAO, there is destruction of the 
inner retinal layer and capillary endothelium which explains no retinal 
neovascularization. NVD in CRAO is due to new vessels from choroidal 
circulation. There is no viable retinal tissue. It has been proposed that there is 
first CAOD, which causes anterior segment ischemia leading to NVI and NVG. 
Decreased perfusion of CRA makes it susceptible to occlusion. Increased IOP is 
from the already existent NVG. 
 
Retinoblastoma 
         Retinoblastoma cells contain VEGF, mRNA and hypoxic conditions 
together resulting in increased production of VEGF which in turn causes NVI and 
NVG. 
  
 
Malignant melanoma 
         Occurrence of NVI correlates with increased tumor size, tumor necrosis 
and extent of overlying retinal detachment. NVI and NVG is also caused by 
irradiation which is used in treatment of malignant melanoma. VEGF and VEGF 
mRNA are not detected in the cells and hypoxia in melanoma cell line does not 
increase VEGF production.NVI in metastatic tumors is due to direct effect of 
tumor secreted angiogenesis factor. NVI in Fuch’s heterochomic iridocyclitis and 
pseudoexfoliation syndrome is due to anterior segment perfusion compromise.          
   
PATHOGENESIS OF NVG 
The basic pathology in neovascularization of iris and angle occurs in 
response to stimulus factor of retinal ischemia. For this process to occur viable 
retinal tissue, a low oxygen tension, venous drainage must be present4. In 1956, 
Wise proposed that retinal capillary or venous obstruction resulted in hypoxia of 
retinal cells and would produce vasoformative factor5. Vascular endothelial 
growth factor (VEGF), an endothelial cell specific mitogen is responsible for this 
cascade6  
 
OTHER DIFFUSIBLE SUBSTANCES INVOLVED IN ANGIOGENESIS 
 
• Pro angiogenic factor 
• Tumor necrosis factor – TNF- α             
• Insulin-like growth factors І and ІІ 7  
• Insulin-like growth factor binding proteins 2 and 3 8  
• Basic Fibroblast growth factor - bFGF9  
• Platelet-derived growth factor 8 
• Interleukin - 6 8. 
 
Under conditions of retinal ischemia VEGF is mainly synthesized by muller 
retinal cell. Intraocular diffusion of VEGF to anterior chamber occurs. Aphakia, 
posterior capsule rupture, post YAG capsulotomy have shown high incidence of 
rubeosis. 
 
Endothelial cells from venules or capillaries release enzymes that disrupt the 
adjacent basement membrane. Adjacent endothelial cells from existing vessels 
migrate towards the source of the angiogenic stimulus, whereas more distal cells 
undergo proliferation. The endothelial cells then elongate, and lumen formation 
occurs. Finally, new basement membrane forms and pericytes surround the new 
capillaries to form mature new vessels. 
 
The neovascularization process begins as endothelial budding from 
capillaries of mainly the minor arterial circle at pupil. Endothelial buds progress to 
become glomerulus-like vascular tufts.  Being new vessels they leak fluorescein. 
These new vessels are thin walled endothelial cells without a muscular layer or 
much adventitia or supportive tissue. There are gaps and fenestrations in 
between these endothelial cells 10. 
 
These new vessel appear on the surface of the iris and ormation of 
fibrovasular membrane which consists of myofibroblasts. These are fibroblasts 
with smooth muscle differentiation 11. They are clinically transparent. They are 
identified by flattening of the usual iris surface architecture. New vessels are 
actually beneath this layer of myofibroblasts. This membrane is present wherever 
there is new vessel. Presence of this membrane at the angle blocks the aqueous 
out flow increasing the IOP despite the appearance of normal open angle.  
 
      The smooth muscle component of myofibril contracts on the surface of iris, 
post pigment layer of the iris is pulled around the papillary margin onto the 
anterior surface, causing ectropion uveae. Contraction at the root of iris leads to 
PAS and further contraction results in synechial angle closure with iridocorneal 
touch. In the late stages the endothelium and descemet”s membrane extends 
from the cornea across the synechiae onto the iris surface 12.  
 
CLINICAL FEATURES 
• The classic feature of NVG is a patient with painful eye 
• Reduced vision 
• Conjunctival congestion 
• Corneal edema 
• Iritis  ⁄  Vitritis 
• Elevated IOP 
• RAPD 
• Neovascularization of iris 
• Neovascularization of angle 
• Synechial angle closure 
• Optic nerve damage 
• Associated Retinopathy 
                        
STAGES OF NVG 13 
The clinical and histologic events lead from a predisposing factor through 
rubeosis iridis to NVG may be classified as 
 
1. Pre-rubeosis stage 
2. Pre-glaucoma stage : rubeosis iridis 
3. Open angle glaucoma stage 
4. Angle closure glaucoma stage  
 
 PRE-RUBEOSIS STAGE 
        The main predisposing factors for rubeosis are diabetic retinopathy and 
central retinal vain occlusion. They go for rubeosis at 43 % and 37 % 
respectively14.  
       
 DIABETIC RETINOPATHY 
High incidence of rubeosis is reported with proliferative type of DR. The 
risk of NVI and NVG in DR is increased when arteriolar or capillary nonperfusion 
or after vitrectomy or lensectomy. There is high correlation between rubeosis 
iridis with disc neovascularization and rhegmatogenous retinal detachment 13.  
 
          Before clinically detectable NVI, iris fluorescein angiography demonstrates 
peripupillary leakage of dye. Thus slitlamp biomicroscope is less reliable than 
angiography. Angle neovascularization may precede that of the iris. So treatment 
is needed prior to clinical detection of rubeosis. 
 
CENTRAL RETINAL VEIN OCCLUSION 
The incidence of NVI and NVG in CRVO is significantly correlated with the 
retinal capillary nonperfusion 13. 
 
Fluorescein angiography is the most direct method of evaluating capillary 
non perfusion. This may not be feasible due to obstruction of visualization by 
blood or other media opacities.  
 
Aqueous protein and cell concentrations by laser flare - cell meter have 
shown to correlate with FFA findings and severity of retinal vein occlusion. RAPD 
indicates the increased risk of rubeosis iridis after CRVO. ERG, flicker ERG, 
color Doppler imaging of blood flow velocities of CRV and CRA provide high 
degree of predictability regarding NVI.    
 
 
 RUBEOTIC STAGE (PREGLAUCOMA STAGE) 
Early in the disease process slitlamp biomicroscopy reveals dilated tufts of 
preexisting capillaries and fine, randomly oriented vessels on the surface of the 
iris near the pupillary margin. These new vessels are characterized by leakage of 
fluorescein. Gonioscopy reveal variable amount of angle neovascularization. 
These neovascular trunks cross the cilliary body band and scleral spur and 
arborize on the trabecular meshwork. 
 
OPEN ANGLE GLAUCOMA STAGE    
New vessel in a CRVO arises about 8 to 15 weeks after the vascular 
occlusive event. It has been called 90 day glaucoma because of the time interval 
- 3 months. Rubeosis iridis is more florid  
 
Aqueous reveals inflammatory reaction. Gonioscopy, reveals 
neovascularization. Angle is open and a fibro vascular membrane covers the 
angle and anterior surface of iris, obstructing the aqueous out flow. The angle 
new vessel arborizes on and into the trabecular meshwork. The IOP is elevated 
with an open angle. Open angle stage is associated with anterior chamber 
inflammation and hemorrhage. 
  ANGLE CLOSURE GLAUCOMA STAGE   
  Stroma of the iris has become flattened, with a smooth glistening 
appearance. The fibrovascular contractile smooth myofibril containing tissue is 
responsible for tissue contraction.  Ectropion uveae develops with distortion of 
pupil. Fibrovascular tissue contraction at the angle leads to PAS and eventually 
angle closure. Iris becomes flattened with a smooth glistening appearance. Iris is 
often dilated and pulled anteriorly. Glaucoma is severe. 
 
MANAGEMENT   
DIAGNOSIS  
A careful clinical examination and history of long term underlying 
pathology like DR, RD is taken. Careful slit-lamp examination reveals 
circumcorneal congestion with corneal edema and anterior chamber 
inflammation. NVI with ectropion uveae may be present. IOP is usually 
intractably high. Fluorescein angiography shows leaking iris vessels.  
      
TREATEMENT 
         This may be considered under these headings. 
1. Prophylactic treatment 
2. Early stage therapy  
3. Late stage therapy 
4. End stage therapy 
 PROPHYLACTIC TREATMENT 
Causes of NVG are mutifactorial. Control of HT, blood glucose, and 
cholesterol levels is the best prophylaxis. Careful follow up of nonischemic CRVO 
and FFA in ischemic type to assess the amount of nonperfusion area is a must. 
In DR patients with PDR, FFA is done to find the nonperfusion areas. 
Prophylactic PRP to ablate ischemic retina will prevent NVI and NVG. 
 
Retinal hypoxia leads to the expression of VEGF, being the basic 
pathology in developing NVI and subsequently NVG. Anti VEGF treatment will be 
good prophylaxis in vitreous with hemorrhage in PDR, Eale’s disease. 
 
PEDF (pigment epithelial derived factor) a potent angiogenesis may be 
administered therapeutically or by viral mediated gene transfer15.  
 
EARLY STAGE THERAPY   
Once NVI is discovered, the mainstay in early therapy is PRP. There is 
60% decrease in vitreous VEGF levels after the laser treatment 16.  
 
During standard PRP, only 13 % of the retinal area is treated. According to 
guidelines of the Diabetic Retinopathy Study, a minimum of 1200 - 1600, 500µm 
sized burns applied randomly over the peripheral retina.This study also states, 
eyes that had more PRP had less risk of visual loss17. So most specialists 
believe that 1500 – 2000 spots using Rodenstack   wide angle contact lens 
(670µm spot size) is necessary to constitute adequate PRP. Krypton laser is 
more effective if some media opacity or retinal hemorrhages is present. 
 
If adequate PRP is given early in the course of NVI, there is regression of 
NVI in CRVO and PDR. If the cause is a detached retina or an ocular tumor the 
early therapy must be directed to the primary cause. 
 
ENDOPHOTOCOAGULATION  
   It is done in situations where preoperative PRP is not possible in eyes with 
NVI. This procedure is widely done in vitreous hemorrhage during vitrectomy. 
 
PANRETINAL CRYOTHERAPY  
It is indicated in cases in which cornea, lens, or vitreous is too hazy for 
adequate PRP. Produces more inflammation and blood-retinal barrier break-
down. After the procedure there is increased influx of macrophages, which has 
an added benefit of clearing vitreous blood. 
 
  GONIOPHOTOCOAGULATION 
Direct laser treatment of NVI eliminates angle vessel in the treated area. It 
also prevents further angle closure. Goniophotocoagulation alone is not 
beneficial. The success rate depends upon adjuvant PRP. 
 
MEDICAL THERAPY 
 All the anti glaucoma medications will be effective to some degree in 
lowering IOP. Two medicines of greatest benefit is, topical Atropine 1 % twice a 
day which reduces ocular congestion. Topical steroids is used four times daily to 
reduce ocular inflammation. 
              
LATE – STAGE THERAPY 
PAN RETINAL PHOTOCOAGULATION 
When synechial angle closure has occurred, it is considered the late 
stage. If possible PRP should still be performed to eliminate the stimulus for new 
vessel formation. PRP does not prevent or reverse the synechial formation but it 
causes regression of new vessels. Regression of new vessel occurs within days. 
Without elimination of new vessel formation, filtration surgery more likely to fail. 
Preferably 3– 4 weeks, should elapse between completed PRP and filtration 
surgery. 
 
 MEDICAL THERAPY 
With extensive synechial closure is established, medications acting on 
aqueous out flow are useless (Pilocarpine). Moreover they are contraindicated as 
they increase hyperemia and inflammation. Medications that decrease aqueous 
production, such as β-blockers and carbonic anhydrase inhibitors, are beneficial.  
 
Topical Apraclonidine is effective on short term basis. Brimonidine and 
prostaglandin analogues have not been evaluated in late stage NVG. Osmotic 
agents can be used intermittently to clear the cornea. 
 
The most important medications are topical atropine and steroids to 
decrease congestion and inflammation18. 
  
 CONVENTIONAL SURGERY 
If there are engorged iris vessels at the time of surgery, intraoperative and 
postoperative hemorrhages are likely to occur. The presence of active 
neovascularization leads to late bleb failure by conjunctival scaring at the 
filtration site. 
  
To prevent postoperative scarring of the filtration bleb, β-irradiation.19, 
Subconjunctival injection of 5-fluorouracil20 and intraoperative Mitomycin – C21 
have been tried. Whatever the surgical procedure, PRP should be performed 
whenever possible22.   
 
FILTRATION TECHNIQUE 
After adequate PRP, topical atropine and steroids are instilled. If IOP is 
high, aqueous production reducing drugs and osmotic agents are used 
preoperatively. This avoids sudden surgical decompression of the hard eye. 
Peribulbar or retrobulbar anesthesia with epinephrine plus orbital massage is 
preferred. 
  A full thickness procedure (e.g.: a trephine or posterior lip sclerectomy) or 
a guarded procedure (e.g.: a trabeculectomy) may be performed. Preference is 
to perform trabeculectomy with MMC.  
 
Preiridectomy-cautery to the iris is done when iris is lifted by forceps to 
prevent bleeding. Postoperative medication includes topical steroids six times per 
day, Cycloplegic agent twice; NSIAD topical drops four times, topical antibiotics 
six times daily. Surgical success of IOP less than 25 mmHg was reported to be 
70 % to 80 %.  
 
GLAUCOMA TUBE IMPLANT SURGERY 
Filtration surgery in NVG should be reserved for eyes that have useful 
vision. Major problem with filtration surgery in NVG is failure of filtration bleb 
through episcleral scarring. This lead to the thought of maintaining an opening 
between anterior chamber and subconjunctival space has formed the basis for 
various Seton procedures. Implants  are widely used in refractory glaucomas and 
NVG.  
 
With Molteno implant there was 83 % success with an IOP less than 20 mmHg 
24.  Krupin-denver valve has 67 % successes rate with IOP less than 24 mmHg 
25. Ahmed and Baerveldt glaucoma valve implant may also used in surgical 
management of refractory NVG 26.    
 
The problems with all stent and shunt procedures in the treatment of NVG 
are the same. They is early postoperative hypotony, blockage of the internal 
fistula, blockage of the external site, and a vigorous postoperative fibrous 
encapsulation response 26 27.  Postoperative hypotony with flat anterior chamber 
is the commonest complication. Modification of Molteno technique using two 
stages24, or suture intubation of the silicone tube28 and introduction of valved 
implants (e.g., Krupin and Ahmed) are valid attempts to avoid early postoperative 
hypotony. 
 
Obstruction of internal fistula is unique to all drainage devices and is 
common in NVG as intraocular bleeding and fibrovascular membranes can block 
the opening of the tube. 
 
CILIODESTRUCTIVE PROCEDURES 
CYCLOCRYOTHERAPY 
When medical therapy does not provide symptomatic relief in end-stage 
NVG, cyclodestructive procedures should be considered. Cyclocryotherapy 
produces hypotensive effect by destruction of secretory ciliary epithelium29.  
 
There is about 63% of successes in controlling IOP but about 40% goes 
for hypotony30.   Phthisis bulbi is another common complication. Standardization 
of treatment protocol was introduced in 1973. Only 180 degrees of ciliary body is 
treated at one time, employing six spots of freezing, 2.5mm posterior to limbus31.  
If saving functional vision is not a factor, and relief of pain is the main 
consideration, then cyclocryotherapy is useful. So it should be reserved for the 
final effort in the treatment of NVG. 
 
 
 
CYCLODIATHERMY 
          The successes rate of IOP less than 25 mmHg equals the phthisis rate. 
Cyclodiathermy appears to be more destructive than cyclocryotherapy. 
 
LASER CYCLOPHOTOCOAGULATION 
         Using slit-lamp or fibreoptic delivery system, mainly the diode and also 
ND:YAG lasers are used. IOP can be controlled and visual results are poor. 
Standardization protocol for NVG is not established. Direct visualization and 
treatment of the ciliary processes is done through transpupillary route using 
endoscope or a goniolens or an intraocular procedure with vitrectomy. 
 
High intensity ultrasonography and intraocular carbon dioxide 
photocoagulation have also been used to destroy ciliary processes. No 
standardization protocol been established for these procedures. 
 
RETROBULBAR INJECTION 
Retrobulbar alcohol or chlorpromazine injection has been reported with 
long-standing relief of pain32.  
 
PROPOSED TREATMENT ALGORITHM 
EYES WITH USEFUL VISION 
 
  1. Treatment of the underlying retinal ischemia and / or inflammation. 
  2. Appropriate retinal ablation procedure 
   3. Residual glaucoma management  
MEDICAL                                   
• Aqueous production reducing topical and systemic.  
SURGICAL 
• Trabeculectomy with Mitomycin C 
• Aqueous tube shunt implant 
• Diode laser cyclophotocoagulation 
  
EYES WITH NO USEFUL VISION 
 In eyes with no useful vision, the goal is patient comfort. Initially, medical 
treatment and in recalcitrant cases surgical intervention like cyclodestruction, 
retrobulbar alcohol injection and enucleation is done. 
 
 
 
 
 
Treatment algorithm for neovascular glaucoma 
 
 
  
 
 
 
RECENT CONCEPTS OF TREATING NVG BY ANTI VEGF 
 
Since there are various modalities in the treatment of NVG, all are aimed 
at reducing the IOP to make the patient comfortable without pain and preserve 
useful vision available. Even though PRP is the golden standard and is useful in 
reducing the retinal ischemia, it destroys the retinal tissue. In patients with media 
opacity such as cataract or vitreous hemorrhage, it is difficult to perform PRP.   
 
Due to the presence of ongoing pathology of retinal ischemia which 
induces the neovascularization, the medical management becomes intractable 
and the surgical procedures has high failure rate, a new modality of 
counteracting the angiogenesis factor is thought off. 
 
  Therefore, direct targeting of VEGF with anti-VEGF pharmacotherapy may 
be another possible therapeutic strategy to treat NVG 33.  
 
IVB facilitates regression or resolution of anterior segment 
neovascularization to stabilize IOP in early-stage NVG with an open angle and it 
may improve the quality and safety of antiglaucoma surgery in advanced NVG 
with angle closure, thus providing long term IOP control.34  
 
 
  Intravitreal Bevacizumab (Avastin) leads to rapid regression of iris and 
angle neovascularization in the management of NVG35.  
 
HISTORICAL INTERESTS IN THE DEVELOPMENT OF ANTIANGIOGENESIS 
As early as 1948, Michaelson postulated the existence of vasoformative 
factor, “X” factor, that controlled the normal development of the new vessels 
during embryogenesis 5 36. Aston and associates in 1954 suggested that excess 
of this factor “X” caused retinal neovascularization in retinal ischemia of ROP. 
 
 In1971, Folkman proposed that anti-angiogenesis might be effective in 
anticancer therapy 37.  
 
In 1983, Sengar, reported the partial purification from the conditioned 
medium of guinea pig tumor cell line of “Vascular permeability factor” (VPF), a 
protein that produced vascular leakage in the skin 38.  
 
In 1989, “Vascular Endothelial Growth factor” (VEGF), an endothelial cell 
specific mitogen, from medium conditioned by bovine pituitary follicular cells was 
isolated39.  
 
Sengar and collaborators independently reported the isolation and 
sequencing of VPF40.  cDNA cloning of VEGF, by Ferrara”s group and of VPF, by 
Connolly”s group, showed that VEGF and VPF were same molecule. 
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) 
VEGF refers to 4 homodimeric polypeptides produced through alternative 
splicing of messenger RNA (mRNA). It is a potent angiogenesis and permeability 
enhancing factor made in retinal cells and VEGF, mRNA levels are dramatically 
increased during hypoxia. 
 
VEGF is essential for normal embryonic vasculogenesis and 
angiogenesis. Plasminogen activation is important in regulating the activity and 
bioavailability in physiological and pathological angiogenesis 41.  
 
 VEGF increases vascular permeability and is important in inflammation 
and in other pathological conditions42. VEGF is mitogenic and the primary target 
is the endothelial cells43.  
 
VEGF induces a potent angiogenic response in a variety of in vivo models 
44. Action of VEGF is to promote the growth of vascular endothelial cells derived 
from arteries, veins and lymphatics 45. 
 
VEGF has significant homology to A and B chains of PDGF 46.  VEGF-A is 
a prototype member of a gene family that includes Placenta Growth Factor, 
VEGF-B, VEGF-C, VEGF-D and orf virus-encoded VEGF-E6.  
  
The gene encoding human VEGF- A is organized in eight exons, 
separated by seven introns47.  
 
Alternative exon splicing results in the generation of four principle isoforms 
namely VEGF-121, VEGF-163, VEGF-189 and VEGF-206, that have 121, 165, 
189 and 206 amino acids respectively following single-sequence cleavage. 46    
Less frequent spice variants have been also reported, including VEGF-145, 
VEGF-183, VEGF-162, VEGF-165b. 
 
Alternate spicing regulates the bioavailability of VEGF. VEGF-121 fails to 
bind Heparin and is freely diffusible protein.VEGF-165 is secreted, but a 
significant fraction remains bound to the cell surface an extra cellular matrix and 
is the most physiologically relevant isoform. Plasmin is able to cleave VEGF-165. 
 
VEGF RECEPTORS 
 VEGF receptors are present on retinal capillary endothelial cells. There 
are two VEGF receptor tyrosine kinases: VEGF-R1, also known as Flt-1 and 
VEGF-R2, also known as Flk-1. VEGF-R2 is the major mediator of the mitogenic, 
angiogenic, and permeability enhancing effect 48. VEGF-R1 is not directly 
involved in mitogenesis and angiogenesis, may function as a “decoy” receptor 
that sequesters VEGF and prevents its interaction with VEGF-R.2. Neuropilin-1 
(NP-1), seems to present VEGF-165 to VEGF-R2 in a manner that potentiates 
VEGF-R2 signaling 49.  
 
EXPRESSION OF VEGF 
VEGF mRNA expression is induced by exposure to low pO2. Oxygen 
tension has a key role in regulating the expression of a variety of genes, 
including VEGF50. 
               
ANTI VEGF 
Administration of VEGF inhibitors delays follicular development and 
suppresses luteal angiogenesis in primates 51. 
 
VEGF-164 blockade led to a significant inhibition of pathological 
Neovascularization with little or no suppression of revascularization and 
physiological Neovascularization 52. 
 
 AVASTIN (BEVACIZUMAB) 
Avastin (Bevacizumab) is a recombinant humanized monoclonal 
immunoglobulin G-1 (IgG), antibody that inhibits human vascular endothelial 
growth factor. It was approved by the United States Food and Drug 
Administration on 26th February 2004 as a first line treatment of metastatic 
colorectal cancer. Bevacizumab is composed of two identical light chains, 
consisting of 214 amino acid residues and two 453 residue heavy chains 
containing an N-linked oligosaccharide and has a molecular weight of 
approximately 149,000 daltons. 
 
Avastin is a clear to slightly opalescent, colorless to pale brown sterile 
solution for intravenous (IV) infusion. Avastin is available in 100 mg and 400 mg 
single dose vials, containing 4 ml and 16 ml, respectively of bevacizumab (25 
mg/ml). Avastin also contains a trialose dihydrate, monobasic monohydrate 
sodium phosphate, dibasic sodium phosphate, polysorbate 20 and water for 
injections. 
 
PHARMACOLOGY 
MECHANISM OF ACTION 
Avastin is an antineoplastic agent containing the active ingredient, 
bevacizumab. Avastin inhibits the binding of VEGF to its receptors, Flt-l (VEGF-
R1) and KDR (VEGF-R2), on the surface of endothelial cells. Avastin binds to 
and neutralizes all human VEGF-A isoforms and does not neutralize other 
members of VEGF family gene, like VEGF-B or VEGF-C. 
  
Neutralizing the biologic activity of VEGF reduces the vascularization of 
tumors, thereby inhibiting tumor growth. Administration of bevacizumab or its 
parental murine antibody to xenotransplant models of cancer in nude mice 
resulted in extensive antitumor activity in human cancers, including colon, breast, 
pancreas and prostate. Metastatic disease progression was inhibited and micro 
vascular permeability was reduced. 
 
 PHARMACOKINETICS 
Nontoxic to the retina and optic nerve at 2.5 mg dose.53 The 
pharmacokinetics of Bevacizumab were characterized in patients with various 
types of solid tumors. The doses tested were 0.1-10 mg/kg weekly in phase I; 3-
20 mg/kg every two weeks (q2w) or every three weeks (q3w) in phase II; 5 mg/kg 
(q2w) or 15 mg/kg q3w in phase III. In all clinical trials, bevacizumab was 
administered as an IV infusion. 
  
As observed with other antibodies, the pharmacokinetics of bevacizumab 
are well described by a two-compartment model. Overall, in all clinical trials, 
bevacizumab disposition was characterized by a low clearance, a limited volume 
of the central compartment (VC), and a long elimination half-life. 
 
Terminal half-life of Avastin in humans is 17 – 21 days. This enables 
target therapeutic bevacizumab plasma levels to be maintained with a range of 
administration schedules (such as one administration every 2 or 3 weeks). 
 
In the population pharmacokinetics analysis there was no significant 
difference in the pharmacokinetics of bevacizumab in relation to age (no 
correlation between bevacizumab clearance and subject age [the median age 
was 59 years with 5th and 95th percentiles of 37 and 76 years]). 
 
Low albumin and high alkaline phosphatase levels are generally indicative 
of disease severity and tumor burden. Bevacizumab clearance was 
approximately 20% higher either in subjects with low levels of serum albumin or 
in subjects with elevated alkaline phosphatase levels when compared with the 
typical subject with median values of albumin and/or alkaline phosphatase. 
ELIMINATION 
 The pharmacokinetics of bevacizumab are linear at doses ranging from 
1.5 to 10 mg/kg/wk. The value for clearance is, on average, equal to 0.207 and 
0.262 L/day for female and male subjects, respectively. After correcting for body 
weight, male subjects had a higher bevacizumab clearance (+26%) than females. 
According to the bi-compartmental model, the initial half-life (α) is 1.4 days for 
both sexes, and the terminal (β) half-life estimate is 20 days for a typical female 
subject and 19 days for a typical male. 
 
ADVERSE EFFECTS  
Adverse effects Includes thrombosis, bleeding, protinuria and 
hypertension Haritoglou et al in his study on 51 patients with diffuse diabetic 
macular edema. treated with a 0.05-mL injection containing 1.25 mg of 
bevacizumab and followed up for 6 weeks54. Mean visual acuity increased at 6 
weeks after injection (P = 0.001), with some regression after 12 weeks. Mean 
retinal thickness decreased at 2 weeks (P = 0.002), at 6 weeks (P = 0.001), and 
at 12 weeks (P = 0.001) and concluded that even in cases of diffuse diabetic 
macular edema not responding to previous treatments such as photocoagulation, 
intravitreal injection of triamcinolone, or vitrectomy, improvement of visual acuity 
and decrease of retinal thickness could be observed after intravitreal injection of 
bevacizumab 
 
           Costa et al in a study on   7 eyes with macular edema associated with 
ischemic central or hemi central RVO treated with intravitreal injections of 2.0 mg 
(0.08 ml) of bevacizumab at 12-week intervals, fluorescein leakage was 
observed in the macula and affected retinal quadrants in all seven eyes55. No 
patient had a decrease in BCVA and concluded that Intravitreal bevacizumab 
injections were well tolerated and associated with short-term BCVA stabilization 
or improvement and favorable macular changes in all patients with ischemic RVO 
and associated macular edema. 
   
          Iturraldo et al in a   retrospective study of 16 eyes  with macular edema 
due to CRVO treated with at least one intravitreal injection of bevacizumab 1.25 
mg in 0.05 ml,  intravitreal bevacizumab resulted in a significant decrease in 
macular edema and improvement in visual acuity56.  
 
         Goff et al in a retrospective study of 51 patients treated with intravitreal 
bevacizumab for CNV from AMD, concluded that IVB for CNV from AMD resulted 
in a rapid decrease in OCT-measured retinal thickness in a majority of cases. 
Visual acuity also improved in this series, suggesting a potential corresponding 
visual benefit57.  
 
          Michel et al in a study evaluating the short-term safety of systemic 
bevacizumab on visual acuity (VA), sub foveal choroidal neovascularization 
(CNV) in patients with neovascular age-related macular degeneration (AMD) 
there was no serious ocular or systemic adverse events58. They concluded that 
overall, bevacizumab therapy was well tolerated, with an improvement in VA, 
OCT, and angiographic outcomes. 
 
 
AVASTIN IN TREATMENT OF NEO VASCULAR GLAUCOMA 
           Wakabayashi et al   in a retrospective, study on 41 eyes with INV or NVG 
secondary to ischemic retinal disorders concluded that Intravitreal bevacizumab 
is well tolerated, effectively stabilized INV activity, and controlled IOP in patients 
with INV alone and early-stage NVG without angle closure. In advanced NVG, 
IVB cannot control IOP59.  
  
           Vatavukz et al concluded that Bevacizumab seems to be a useful adjunct 
to PRP in the treatment of neovascular glaucoma60. 
 
           Milko et al in a retrospective study of  6 patients with NVG who had 
received 1.25 mg/0.05 ml IVB. Diode laser cyclophotocoagulation was carried if 
pressure not controlled sufficiently by topical medication and followed for period 
of 4 to 16 weeks. IVB resulted in marked regression of anterior segment 
Neovascularization and relief of symptoms with in 48 hours61  
    
           Deepa et al in a study on 14 eyes of 12 patients treated with IVB and PRP 
concluded that long-term preservation of open angle and IOP control in eyes 
receiving bevacizumab along with PRP stressed that NVG is still associated with 
poor visual acuity outcomes62. 
 
           Moataz et al in a study on 6 cases of NVG studied and followed for a 
period of 3–19 months (average, 9.7 months) after 1.25 mg (0.05 cc) of IVB 
followed by pan retinal photocoagulation (PRP) approximately 1 week later 
showed complete regression of iris and anterior chamber angle 
neovascularization in all patients. They concluded that IVB may be a valuable 
addition in the treatment of NVG by hastening the resolution of anterior segment 
neovascularization, improving the results of glaucoma surgeries, and appears to 
give long-term control when used in combination with PRP64.  
 Other anti VEGF agents:70 
• Pegaptanib Sodium  
• Ranibizumab 
• VEGF trap  
 
PEGAPTANIB SODIUM 
Pegaptanib sodium is an anti VEGF aptamers. Aptamers are 
oligonucloetides designed to bind with specific molecular targets. This agent is a 
polyethylene glycol (PEG) – conjugated oligo nucleotide that binds specifically to 
VEGF 165 isoform 69.  
However because of its selective binding it is no longer considered to be as 
effective as Ranibizumab and Bevacizumab.  
 
 
RANIBIZUMAB  
Lucentis is a second generation antibody with reduced size that allows it 
to penetrate all of the retinal layers. The drug is a 2 – part humanized monoclonal 
antibody fragment against VEGF. It is an antigen binding murine derived epitope 
with a  non binding human sequence added to reduce the antigenicity in 
primates. It binds to 121, 165 and 110 isoforms. It is  approved for use in 
exudative ARMD. 
 
Anecortave acetate is a corticosteroid derivative found to inhibit 
angiogenesis induced by basic fibroblastic growth factor ( b FGF) and VEGF as 
well as other known stimulators of angiogenesis .  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and methods 
MATERIALS AND METHODS 
 A prospective randomized study on 15 eyes of 15 patients with neovascular 
glaucoma attending the Glaucoma service at Institute of Ophthalmology Joseph 
Eye Hospital, Tiruchirapalli, between May 2008 to October 2009 was conducted. 
Eyes receiving one or more doses of intravitreal Bevacizumab were studied.  
  
 Informed consent was obtained from all patients after discussing the 
benefits and potential risks and alternative treatment. The procedures used 
conformed to the Tenets of the declaration of Helsinki and was approved by the 
ethics committee board of the institute. 
 
INCLUSION CRITERIA 
  
1. Patient with a clinical diagnosis of neovascular glaucoma by slit lamp 
evidence of neovascularization of iris/ and angle and elevated IOP. 
2. Neovascular glaucoma not controlled by maximum medical therapy 
3. Presence of underlying cause for retinal  ischemia i.e. CRVO, Vitreous 
Hemorrhage, advanced PDR 
4. Patient willing for and receiving IVB 
5. No systemic contraindication for IVB 
6. Follow up for at least 6 months 
 
 
EXCLUSION CRITERIA 
 
1. Systemic contraindication for intravitreal injection  
2. Medically controlled NVG 
3. Patient lost to follow up 
4. NVG due to intraocular tumor 
5. Anterior segment pathology interfering with IOP measurement  i.e. 
ptreygium 
  
 All patients underwent a complete clinical examination including best 
corrected visual acuities with Snellen chart, slit lamp bio-microscopic 
examination, IOP measurement using Goldmann applanation tonometer, 
gonioscopic examinations using Goldmann 3-mirror lens. If necessary, fundus 
fluorescein angiography and fundus examination was done by a retina consultant 
to evaluate the pre existing cause of ischemic retinal disorder. Preoperative pan 
retinal photocoagulation and postoperative PRP was given whenever necessary. 
B-scan Ultrasonography to evaluate posterior segment status done to patients 
wherever the media is hazy. A complete systemic examination was done by an 
internist and fitness for intravitreal injection was obtained. IOP was well 
controlled by maximal medical therapy before IVB was given. 
 
 Commercially available bevacizumab (Avastin Genentech, Inc., South San 
Francisco, CA) (Avastin 25mg/ml) was prepared for each patient and was placed 
in tuberculin syringe with 26 gauge needle. 
 
 Under topical anesthesia with 4% lidocaine eye drops and 1.25% povidone 
– iodine solution was instilled. Using a caliper a marking of 4mm from the limbus 
was made in the infero-temporal quadrant using gentian violet. 0.1ml of 
bevacizumab (1.25 mg) was injected intravitreally via pars plana under 
visualization wherever possible. Postoperatively Tab. Acetazolamide 250mg 3 
times daily, Dorzolamide eye drop 3 times daily, Timolol maleate 0.5% eye drop 
twice daily, Prednisolone acetate 1% eye drop 4 to 6 times daily, Ofloxacin eye 
drop 0.3% 6 times daily with non steroidal anti-inflammatory tablet orally was 
advised in all . 
 
 Postoperative follow up examinations were performed 3 day, 1 week, 1 
month, 3 months, 6 months after the intravitreal bevacizumab. During each follow 
up a complete clinical examination including best corrected visual acuities with 
Snellen chart, slit lamp bio-microscopic examination, IOP measurement using 
Goldmann applanation tonomete, gonioscopic examinations using Goldmann 3-
mirror lens and the regression and reccurrence of NVI, NVA and the need of 
additional or withdrawal of antiglaucoma medication was decided. Visual acuity 
was measured using Snellen acuity chart.  
 
 Complete success was defined as regression of NVI, relief of pain with 
tolerable IOP (± medical therapy) in the absence of phthisis and without the need 
of further surgical procedures. 
 
 When a surgical intervention such as cyclodestructive procedure like trans- 
scleral cyclophotocoagulation were performed, IVB therapy was considered 
failed.  
Qualified success was defined as control of IOP and pain with additional non-
destructive surgery such as trabeculectomy or additional pan retinal 
photocoagulation. 
 
 Statistical analysis was performed using SPSS (version 10.0) p value ≤ 0.05 
was considered statistically significant. 
  
  Repeat injection of intravitreal bevacizumab was performed in patients if 
there is no regression or reappearance of NVI with increase in pain and 
symptoms despite, IVB, additional PRP and maximum tolerable anti-glaucoma 
topical medications. 
 
 
 
  
 



  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
RESULTS 
          
           Fifteen eyes of 15 patients were enrolled in the study out of which 11 were 
males (73.3%) and 4 were female (26.6%). Mean follow up period was 12.4 ± 
3.52 months (6 –18 months). The mean age of the patients was 65.53 ± 8.57 yrs 
(range- 52-78 yrs).  
 
 Of these 15 eyes, 7eyes had NVG with open angles and 8 had NVG with 
angle closure. The patient demographics and baseline characteristics are shown 
in Table-1.  
       
 Underlying cause for neovascularization was retrospectively analyzed in 
all the 15 patients. In 11 patients, CRVO (73.33%) was the cause while in 2 
patients CRVO along with PDR (13.3%) was found to be the cause. Posterior 
uveitis was the  underlying cause in one (6.67%) and  PDR alone was the causes 
for NVG for one eye  (6.67%). 
 
  The mean IOP at the time of presentation in 15 eyes was 52.13±12.93 mm 
Hg (range, 28-72). The mean IOP before IVB with medical management was 
36.13 ± 11.92 mm Hg (range, 16–56) and at 1st visit after IVB was 34.8±12.23 
mm Hg (range, 16–64). The mean IOP at the end of follow-up (post IVB with 
medical management) was 37.20 ± 21.30 mm Hg. (Table - 2) 
 
        The mean reduction in IOP from the time of presentation to that before IVB 
was 16.00±12.26 mm Hg was statistically significant,(p=0.000). The mean 
reduction in IOP recorded at first follow-up (after IVB) from that at presentation 
was 17.33±11.07 mm Hg which was statistically significant (p=0.000). The mean 
reduction in IOP  from the time of presentation to that at final follow-up (after IVB) 
was 14.93 ± 20.04 mm Hg which was also statistically significant, (p=0.012). 
(Table 3) 
          
          The mean reduction in IOP recorded at first follow up visit (after IVB) from 
that before IVB (after medical management) was 1.33±13.51 mm Hg which was 
also statistically significant, (p=0.708) 
 
 At the first follow up, out of the fifteen eyes, only one (6.67%), experienced 
a rise in IOP, when compared to the IOP at the time of presentation. At the final 
follow up, out of 15 eyes, 5 eyes (33.33%) had persistent  high  IOP when 
compared to the IOP at the time of presentation. 
 
         Regression of NVI on first follow-up after IVB was studied in all 15 eyes and 
13 out of 15 eyes (86.6%) had significant NVI reduction while 2 eyes (13.3%) had 
no signs of neovascular regression. Out of 15 eyes, 6 eyes (14%) had 
neovascularization involving the angle. All  these cases showed  regression of 
neovascularization at angle at first follow – up. 
 
  
        PRP was given before IVB in 7 eyes out of 15 (46%) and PRP post 
IVB in 9 eyes (60%). Three eyes (20%) received PRP both before and after IVB. 
One patient did not receive PRP at all. 
 
 Eyes which required repeat intervention was studied and 2 eyes out of 
15 eyes (13.3%) required repeat IVB. Of the 2 eyes who received repeat IVB one 
eye was given IVB after 6 months and the other at 8 months.         
 
 Four eyes underwent surgical intervention. Of these, 3 underwent 
trabeculectomy with cataract surgery and the remaining one eye had 
cyclocryotherapy. 
 
                 Subjective reduction of pain and discomfort was seen in 14 eyes out of 
15 (93.33%).  
 
 Improvement in visual acuity was seen in 2 eyes out of 15 (13.3%) 
while 13 eyes (86.6%) didn’t show any significant improvement in VA when 
compared to the VA at the time of presentation. These 2 eyes, whose visual 
acuity improved were the ones who had underwent surgical intervention. 
 
              
 
  
      Adverse systemic and local complications related to IVB were monitored for 
all the patients throughout the study. Complications such as hypertension, 
myocardial or cerebral infarction, cataract - progression, uveitis, or 
endophthalmitis was not observed in any of the patients throughout the period of 
study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AGE( in yrs) NO. OF CASES 
51 to 60 6 
61 to 70 4 
71 to 80 5 
73%
27%
GENDER DISTRIBUTION
MALE FEMALE
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GENDER NO. OF PATIENTS 
MALE 11 
FEMALE 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LENS STATUS  NO. OF EYES
CRYSTALLINE LENS  9
PSEUDOPHAKIC  6
 
 
 
 
 
 
STAGE OF NVG  NO. OF EYES 
OPEN ANGLE  7 
ANGLE CLOSURE  8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CAUSE  NO OF EYES 
PDR 1 
CRVO 11 
PDR/CRVO 2 
POSTERIOR UVEITIS 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
NVI REGRESSION  NO. OF EYES 
YES  13 
NO  2 
 
 
 
 
 
 
 
  MEAN IOP (mmHg) 
IOP AT PRESENTATION  52.13 
IOP BEFORE IVB  36.13 
IOP POST IVB  1 ST FOLLOW UP  34.8 
IOP POST IVB LAST VISIT   37.2 
 
 
 
 
 
 
 
 
TABLE - 1.    DEMOGRAPHIC CHARACTERISTICS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Gender   
                        Males  11 
Females 4 
Mean age  65.53± 3.52 ( 52 ‐ 78 years ) 
Follow up period  12.4±3.52  (6‐8 months) 
Stage   
               Open angle   7 
Angle closure 8 
Lens status   
Crystalline lens 9 
                         Pseudophakia  6 
Underlying disease   
          CRVO  11 
PDR & CRVO 2 
      PDR  1 
  POST.  UVEITIS 1 
 
 
 
TABLE - 2.  OBSERVATIONS OF MEAN IOP  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No. of eyes = 15 
 
 
Mean IOP (mmHg)  
IOP AT PRESENTATION 
 
52.13±12.92 
 
 
IOP BEFORE IVB 
 
36.13±11.91 
 
 
 
 
IOP DIFF BET POST IVB AND AT FIRST 
FOLLOW UP VISIT 
 
 
34.80±12.23 
 
 
 
IOP DIFF BET POST IVB AND AT THE 
END OF FOLLOW UP 
 
 
37.20±21.29 
 
 
 
 
 
 
TABLE - 3. CHANGE IN IOP 
 
 
 
 
 
 
 
 
 
 
 
 
IOP DIFFERENCES MEAN P 
VALU
E 
 
IOP at presentation versus IOP Before IVB 
 
16.000 ±12.25 
 
0.000
 
IOP at presentation versus IOP After IVB 1st visit 
 
17.333 ± 11.07 
 
0.000
 
IOP at presentation versus IOP at end follow up 
 
14.933 ± 20.04 
 
0.012
 
IOP Before IVB versus IOP After IVB 1st visit 
 
1.333 ± 13.51 
 
0.708
 
IOP Before IVB versus IOP at  final follow up -1.067 ± 18.32 0.825
 
IOP After IVB Ist visit versus IOP at end follow up -2.40 ±14.18 0.523

  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
 
DISCUSSION 
 
Inspite of various modalities available for the treatment of NVG, all are 
aimed at reducing the IOP and making the patient comfortable, without pain and 
preserve the useful vision available. Due to the presence of ongoing pathology of 
retinal ischemia which induces the neovascularization, as the medical 
management becomes intractable and the surgical procedures has high failure 
rate, new modalities of counteracting the angiogenesis factor  are under trial. 
 
  Therefore, direct targeting of VEGF with anti-VEGF pharmacotherapy may 
be another possible therapeutic strategy to treat NVG 33.  
 
 Recent encouraging results from several small case studies of IVB in the 
treatment of NVI, NVG or both has promoted, to consider the drug Bevacizumab 
(Avastin) as the first treatment of choice for NVG, secondary to underlying 
ischemic retinal disorders. 
 
   Fifteen eyes of 15 patients were enrolled in our study.  
   
 In our study male (73.3%) to female (26.6%) ratio was 11:4. In a 
similar study done be Wakabayashi et al 59   the male (76.6 %) to female (23.4 %) 
ratio was 23:7. 
 
 In our study the mean age of the patients was 66.53 ± 8.57 (range 
52 – 78).In a similar study by Wakabayashi et al 59   and Miliko E et al 61  maen 
age of patients was 57.3 ± 9.6 yrs and 78.4 ± 7.5 yrs respectively.  
 
 
  In our study the underlying cause for neovascularization was 
retrospectively analyzed in all the 15 patients. In 11 patients, CRVO (73.33%) 
alone was the cause while in 2 patients CRVO along with PDR (13.3%) was 
found to be the cause. Posterior uveitis and PDR alone was the causes for NVG 
for one eye each (6.67%). 
 
            In a study by Wakabayashi et al 59   PDR (83%) was the major 
cause for NVG in contrary to our study where CRVO (73.3%) is found to be the 
major cause. In another study done by Miliko E et al 61 the major underlying 
cause was CRVO (83.33 %). In the study done by Karl Ulrich et al 56.2 % had 
only CRVO as the primary cause while 43.8 % had PDR as the cause for NVG. 
A study done by Brown et al where he studied 208 consecutive cases of NVG 
diagnosed over 4 years, 36 % had CRVO, 32 % had DR and 13 % had Ischemic 
heart disease 
.  
 The mean difference between the IOP at presentation and the IOP 
taken before IVB was 16 ± 12.26 mmHg. This was statistically significant 
(p=0.000).  After giving IVB, the change in IOP was (17.33±11.07 mmHg) 
highly significant.(p=0.00) 
 There was also a statistically different decrease in the IOP when 
comparing IOP at the time of presentation and that measured at the last follow up 
visit of the patient.(14.93 ± 20.04 mmHg) ( p=0.012 ). 
  
 Similarly there was no significant difference in the IOP before IVB 
and after IVB to the IOP at the last follow up in our study (p=0.825) and 
(p=0.523) respectively.  Wakabayashi et al 59 in his study using IVB to treat NVG 
secondary to Ischemic retinal disease done in 41 eyes, found that the IOP 
decreased rapidly to nearly normal level to IVB mono therapy in 53 % of eyes 
with open angle NVG, but failed to control IOP (73 %) in the closed angle NVG 
group suggesting the efficacy of IVB in selected cases.  
 
 In our study NVI regression was seen in 86.66% during the first visit 
after IVB, 85.71 % (6 of 7eyes) in open angle stage and 87.5 % (7of 8 eyes ) in 
angle closure stage.  Wakabayashi et al 59 showed NVI regression with 
successful normalization of IOP in 71% of patients with open angle stage and 
rapid NVI regression but failed to normalize the elevated IOP in most cases. Both 
the studies resulted in regression of NVI during the first week after the IVB. 
Yusuke et al who studied the regression of NVI after IVB injections in patients 
with PDR found regression of NVI in all the eyes from one week after injection. 
According to Gheith et al, there was a complete regression of iris and anterior 
chamber angle neovascularization in all the six cases in his study on role of IVB 
in neovascular glaucoma 
. In our study we have not monitored the role of PRP in the 
regression of neovascular changes. PRP before IVB was administered in 7 eyes 
out of 15 eyes (46%) and PRP post IVB in 9 eyes (60%). Three eyes (20%) 
received PRP both before and after IVB. One patient did not receive PRP at all. 
In a study done by Miliko et al 61, 2 eyes (33%) out of 6 eyes had pre IVB PRP, 
and 4 eyes (66%) out of 6 eyes had post IVB PRP. Deepa Vasudev et al 61 has 
also concluded in her study that long term preservation of open angle and IOP 
control was better with eyes receiving bevacizumab along with PRP. 
 
 Out of 6 patients who required repeat intervention, 2 eyes had to 
receive repeat IVB which was given in one eye after 6 months and the other at 8 
months. The rest four underwent surgical intervention. Of these, 3 underwent 
trabeculectomy with cataract surgery and the remaining one eye had 
cyclocryotherapy. In the study done by Wakabayashi et al59 56.25% (18/32) of 
patients with neovascular glaucoma required repeat IVB injection. In his study 11 
eyes out of 15 (73 %) required early surgical within one week of initial IVB 
injection, and a total of 14 eyes out of 15 (93 %) underwent surgery to stabilize 
the elevated IOP in the NVG with angle closure. 
 
 In our study subjective evaluation of pain and discomfort showed a 
decrease in 14 eyes out of 15 (93.33%). This can be compared by the study 
done by Miliko et al in his study where all the patient had relieve of pain and 
discomfort.  
          
 Improvement in visual acuity was seen in 2 eyes out of 15 (13.3%) 
while 13 eyes (86.6%) didn’t show any significant improvement in VA at the end 
of the study. These 2 eyes whose visual acuity improved had underwent cataract 
extraction with trabeculectomy. Studies done by Parrish et al and Tsai et al 
shows that  not only IOP normalization but also visual stabilization is achieved by 
IVB. 
 
 Adverse systemic and local complications related to IVB were 
monitored for all the patients throughout the study and no adverse effect was 
found in all the cases in our study. MARINA trial recorded adverse effects like 
uveitis and presumed endophthalmitis in 1.7 % in anti VEGF treated subjects and 
other thrombo-embolic events such as MI, strokes and vascular deaths was 
found more in anti VEGF treated subjects than controls. Bevacizumab alone 
didn’t cause adverse effects when systemically used along with chemo therapic 
agents in a study on efficacy on buvacizumab in colo-rectal cancer done by 
Hurvitz et al. 
 
 Our study shows use of IVB in NVG facilitates regression and 
resolution of anterior segment neovascularization, stabilization of IOP, relief of 
pain and discomfort without causing any adverse side effects. However the effect 
of Bevacizumab on regression of NVI may be transient due to its short half life 67. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
 CONCLUSION 
  
 Iris neovascularization and subsequent development of 
neovascular glaucoma are serious complications in patients with proliferative 
diabetic retinopathy (PDR) and other ischemic retinal disorders.  
 
 Our study shows that there is a rapid regression of anterior 
segment neovascularization and IOP stabilization in patients with NVG. 
Intravitreal Bevacizumab is an effective primary therapeutic procedure as it 
facilitates regression and resolution of anterior segment neovascularization and 
IOP reduction and long term IOP stabilization in both stages of Neovascular 
glaucoma. 
 
 Adjuvant antiglaucoma medications and PRP are also 
indispensable in the effective control of IOP. In patients requiring filtering 
procedures, IVB improves the outcome of the procedure. 
 
 IVB also reduces symptoms like pain and discomfort in eyes with 
NVG, although in our study there was no improvement in visual acuity IVB seems 
to improve the outcome of the surgical interventions.  
Therefore IVB promises to be a important  intravitreal drug in the management of 
NVG. 
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Proforma 
 
PROFORMA 
Case no:   
Name: MRD no    
Age: RE/LE 
Sex 
Systemic illness: Cardiac/DM/HT/Asthma/ Others 
Pain and discomfort: 
Treatment history: 
                    PRP                                   : 
                    Antiglaucoma medications: 
 Ocular examination  
     Visual acuity 
           Uncorrected  
           BCVA 
     Slit lamp  
           Cornea  
           AC  
           Iris – NVI 
           Pupil  
           Lens  
           Applanation IOP 
           Gonioscopy – open angle, closed angle, angle NV 
Fundus   
         Vitreous hemorrhage  
Underlying ocular cause 
Date of Avastin injection  
          1st injection          : 
          Repeat injections: 
 
Follow up: (during each follow up) 
           Visual acuity  
           S/L examination  
            IOP 
           Gonioscopy  
           Neovascular regression  
                Angle 
                Iris  
           Fundus  
           PRP  
 Treatment: 
        Medical  
        Surgical 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Master charts 
  
 
 
 
 
 
 
 
 
 
 
 
 
Sl No NAME AGE GENDER ASSO SY DISEASE PREX GL RE LE BASE LINE VN UND LY CAUSE  Pre PRP Post IVB PRP IOP AT PRES I st IVB 
I
O
P
 
B
e
f
 
I
V
B
1 Q 60 F DM  &  HT NVG CFCF PDR/CRVO Yes Yes 68 19 - 8 - 08 
2 T 78 M PNAG NVG HM post uvietis 72 27 - 7 - 09 
3 V 58 M DM NVG HM CRVO Yes Yes 40 28 - 6 - 09 
4 S 75 F DM  &  IHD NVG NO PL PDR Yes 28 06/02/2009 
5 M 54 F DM  &  HT     NVG 1 by 60 CRVO Yes 72 06/10/2009 
6 D 74 M DM &  HT NVG PL + CRVO Yes 56 16 - 6 - 09 
7 A 76 M NVG NO PL CRVO 62  7 - 4 - 09 
8 N  70 M HT  &  IHD NVG PL + CRVO Yes 44 03/10/2008 
9 S 60 M HT NVG NO PL CRVO Yes 50 18 - 2 - 08 
10 D 52 M DM NVG PL + PDR /CRVO Yes 56  6 - 6 - 08 
11 R 70 M DM &/  HT NVG 1/2 by 60 CRVO Yes 42 24 - 10 - 08 
12 N 65 M DM  &  HT NVG 1 by 60 CRVO Yes Yes 44 21 - 8 - 08 
13 A 57 M DM  &  HT NVG 1 by 60 CRVO Yes 60 26 - 8 - 08 
14 S 72 F DM NVG PL + CRVO Yes 42 21 - 4 - 08 
15 P 62 M DM NVG NO PL CRVO Yes 46 09/02/2008 
